Thomas H. Pike

Mr. Pike has been a Director since 2019. Mr. Pike was appointed President and CEO of Clinical Development at Labcorp in January 2023. As previously announced by Labcorp, Clinical Development is planned to be spun out later this year in 2023 as an independent company named Fortrea, where Mr. Pike will serve as Chairman of the Board and CEO.

Mr. Pike served as CEO and a member of the Board of Directors of Quintiles Transnational Holdings, Inc., a leading fully integrated biopharmaceutical services company offering clinical, commercial and consulting solutions worldwide, from April 2012 until its merger with IMS Health in 2016 to create IQVIA (NYSE: IQV). Mr. Pike led Quintiles through a successful public offering and helped it grow into a Fortune 500 company. Under Mr. Pike’s leadership, Quintiles was named one of the world’s Most Ethical Companies in 2016. Mr. Pike retired in 2016 after Quintiles’ merger with IMS Health.

Prior to Quintiles, Mr. Pike spent 22 years at Accenture (NYSE: ACN), a leading global professional services company, providing a broad range of services and solutions in strategy, consulting, digital, technology and operations, until 2009. At Accenture, Mr. Pike’s roles included serving as Chief Risk Officer and Managing Director of the North America Health and Products business areas. Prior to that, Mr. Pike was the global Chief Operating Officer for Accenture’s Resources operating group and had also served as Accenture’s Chief Strategy Officer.

After leaving Accenture in 2009 and until joining Quintiles in 2012, Mr. Pike was involved with a number of start-ups in the technology and healthcare sectors. Early in his career, Mr. Pike was a consultant at McKinsey & Company.

Mr. Pike earned his Bachelor of Science in accounting from the University of Delaware.

Independent Director